ArticleCancer cell2022
Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes.
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Exploring SERTAD4 as a prognostic biomarker and therapeutic target in breast cancer: insights from multidatabase analyses and in vitro studies.Clinical and experimental medicine · 2025Article
- Sparse vertex discriminant analysis: Variable selection for biomedical classification applications.Computational statistics & data analysis · 2025Article
- CYB561 is a potential therapeutic target for breast cancer and is associated with immune cell infiltration.European journal of medical research · 2024Article
- Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.Cancer cell international · 2024Article
- Smart DNA sensors-based molecular identification for cancer subtyping.Smart molecules : open access · 2023Review
- RAB10 promotes breast cancer proliferation migration and invasion predicting a poor prognosis for breast cancer.Scientific reports · 2023Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic landscape of breast cancer is becoming increasingly complex. In this issue of Cancer Cell, Wolf et al. present a breast cancer classification scheme that allows for better prediction of treatment response and can be continuously adapted to guide prioritization of new treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.